LENZ Therapeutics (NASDAQ:LENZ) Given New $29.00 Price Target at Bank of America

LENZ Therapeutics (NASDAQ:LENZ) had its target price cut by Bank of America from $35.00 to $29.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen cut shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Finally, William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, LENZ Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $50.20.

LENZ Therapeutics Stock Performance

Shares of LENZ stock opened at $9.07 on Wednesday. The company has a market capitalization of $283.80 million, a P/E ratio of -3.23 and a beta of 0.52. The company’s 50 day moving average price is $14.14 and its two-hundred day moving average price is $24.40. LENZ Therapeutics has a 52 week low of $8.85 and a 52 week high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $3.09 million. Analysts forecast that LENZ Therapeutics will post -2.18 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of LENZ Therapeutics during the third quarter worth $27,000. Bfsg LLC acquired a new position in shares of LENZ Therapeutics in the third quarter valued at about $30,000. State of Wyoming acquired a new position in shares of LENZ Therapeutics in the fourth quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new position in LENZ Therapeutics during the fourth quarter worth about $32,000. Finally, Osaic Holdings Inc. raised its stake in LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after purchasing an additional 1,116 shares in the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics News Roundup

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Bank of America cut its price target from $35 to $29 but kept a “buy” rating, signaling continued analyst conviction in LENZ’s upside despite the reduction in target. Bank of America lowers PT to $29, keeps buy
• Positive Sentiment: Company reports and press coverage say the launch of LNZ100 exceeded expectations and could open a sizable market opportunity if uptake continues. This product news supports longer‑term revenue scenarios. LNZ100 launch story
• Positive Sentiment: LENZ outlined a 2026 acceleration strategy and expanded its VIZZ sales force to 117 reps, a commercial investment intended to drive growth and support the new product rollout. Sales force expansion article
• Neutral Sentiment: Management emphasized a strong cash position on the Q4 call, which reduces near‑term financing risk but doesn’t offset near‑term revenue weakness on its own. Earnings call highlights
• Neutral Sentiment: Reports show a reported “large increase” in short interest for March, but the published figures contain zeros/NaN and an apparent data error — monitor for corrected filings. (No reliable source link available)
• Negative Sentiment: Q4 results missed expectations: EPS of ($1.16) missed consensus and revenue of $1.59M fell well short of estimates; the miss triggered headlines that shares hit an all‑time low. These operating shortfalls are the primary near‑term catalyst weighing on the stock. MarketWatch: shares hit all-time low Earnings release/transcript

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.